Drug Trial Radar · NCT00535925
Nephropathy In Type 2 Diabetes and Cardio-renal Events
Last checked: Nov 19, 2026Latest source record: Aug 3, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
850
Actual
Start
Oct 2005
Primary completion
Dec 2011
Study completion May 2019
Sponsor
- Lead sponsor
- University of Campania Luigi VanvitelliAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 27, 2007
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- All sexes, from 40 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The NID-2 study, a multicentric study (21 centres enrolled), was planned in two phases: Phase 1(observational study, completed in September 2005): after the identification of a type-2 diabetic population with typical Diabetic Nephropathy (DN), to study of the rate of renal and cardiovascular events during a middle term follow-up. Phase 2(interventional study, started in October 2005): after randomization in two groups, a group (intervention group) is treated with an intensive multifactorial intervention whose aim is to reduce morbidity and mortality due to diabetic complications. The other group (control group) continues the conventional therapy . To avoid bias in the treatment in each center, the randomization was performed for centre.
Conditions
- Diabetic Nephropathy
Interventions
SoC therapyDrug
the patients have to be treated according the standard good medical practice by any center
irbesartanDrug
Therapy for hypertension: \- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die
ramiprilDrug
Therapy for hypertension: \- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die
hydrochlorothiazideDrug
Therapy for hypertension \- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)
furosemideDrug
Therapy for hypertension \- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine \<2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)
amlodipineDrug
Therapy for hypertension \- Step 3: amlodipine up to 10 mg/die
atenololDrug
Therapy for hypertension \- Step 4: atenolol up to 100 mg/die
doxazosinDrug
Therapy for hypertension \- Step 5: doxazosin up to 4 mg/die
clonidineDrug
Therapy for hypertension \- Step 6: clonidine
insulinDrug
Therapy for Hyperglycaemia (to achieve HbA1c \<7): \- insulin
simvastatinDrug
Therapy for hypercholesterolemia: \- for reducing LDL cholesterol \< 100 mg/dl: simvastatin up to 80 mg/die
fibrateDrug
Therapy for hypertriglyceridemia \- for reducing triglycerides \< 150 mg/dl and/or increasing HDL cholesterol \> 40-50 mg/dl: a fibrate
erythropoietinDrug
Treatment of anaemia: \- erythropoietin
aspirinDrug
Antiplatelet therapy (in all patients without contraindications): \- aspirin up to 160 mg/die
Primary outcomes
What the sponsor says the trial is designed to measure.
- "Number of Participants With Overall Fatal and Non-fatal, Major Adverse Cardiovascular Events (MACEs)"Time frame: 4 years (in the case the number of events needed by sample size is not reached at the expected 4-year time frame, primary end point will be assessed after the follow-up phase)
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Advanced Medical and Surgical Sciences, Università della Campania "Luigi Vanvitelli", Naples, Italy
Naples, Italy
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.